NEW analyses from Harvard
researchers has indicated that long
term use of vitamin C and E does
not increase cancer risk.
In contrast with previous work
such as the SELECT trial, the
present analysis, which was a post
trial follow-up of the Physicians’
Health Study II (PHS II), revealed
that vitamin E supplementation
every other day and daily vitamin
C supplementation had no effect
on total cancers, the incidence of
prostate cancer and other sitespecific
cancers.
PHS II ended in 2007 and the post
trial follow-up period was 3.8 years
beyond eight years of intervention.
The Harvard authors wrote in
the American Journal of Clinical
Nutrition that the findings
confirmed initial trial results and
indicated that vitamin E and C
supplement use had no immediate
or long-term effects on cancer risk.
CLICK HERE to read the abstract.The above article was sent to subscribers in Pharmacy Daily's issue from 29 Jul 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 29 Jul 14
BREAST Cancer Network Australia (BCNA) has welcomed a PBAC recommendation to subsidise the breast cancer drug Enhertu (trastuzumab deruxtecan) for HER2-low metastatic breast cancer on the PBS.
PHARMACY Connect (PC2024) has revealed that Olympian Peter Bol will be sharing his journey from adversity to athletic greatness at the conference in Sep in Sydney.
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.